A MEMORANDUM of understanding between three industry giants and Singapore’s public sector was signed today, which aims to develop the country’s pharmaceutical manufacturing centre.
The initiative, called the Pharma Innovation Programme Singapore (PIPS), involves GlaxoSmithKline (GSK), Pfizer, Merck Sharp & Dohme (MSD), the National University of Singapore (NUS) and The Agency for Science, Technology and Research (A*STAR).
It aims to improve and transform the manufacturing operations and technologies of the industry, focussing upon continuous manufacturing, bio-catalysis, process analytical technology, advanced process control, and enhanced pharmaceutical operations.
Speaking at the Future of Manufacturing Summit today, Singapore’s minister for trade and industry S Iswaran said: “The vision is for Singapore to lead the way in the global transformation of pharmaceutical manufacturing to create unique value for patients, the pharmaceutical industry and for Singapore.”
He said that the partnership has the potential to pave the way for many more collaborations between the public sector and industry, even among companies that compete in the marketplace.
“Given the complex and dynamic nature of the future of manufacturing, it is important for us to strengthen the partnerships within the local manufacturing ecosystem in order to pool resources, share risk and increase adoption rates,” Iswaran added.
The Future of Manufacturing Summit is organised by A*STAR, and kicks off a two-week series of events to develop and sustain the country’s industry capabilities.
Catch up on the latest news, views and jobs from The Chemical Engineer. Below are the four latest issues. View a wider selection of the archive from within the Magazine section of this site.
